PRR18 Activators
Chemical activators of PRR18 can initiate a cascade of intracellular events leading to its activation through various mechanisms involving the modulation of signaling pathways. Forskolin, a diterpene, serves as a direct stimulant of adenylyl cyclase, thus increasing the levels of cAMP within the cell. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate PRR18, resulting in its activation. Similarly, Isoproterenol, by binding to beta-adrenergic receptors, triggers a comparable increase in cAMP levels, providing another route for PKA-mediated phosphorylation of PRR18. IBMX, by inhibiting phosphodiesterases, prevents the breakdown of cAMP, thereby indirectly contributing to the accumulation of cAMP and subsequent PKA activation. Prostaglandin E1 (PGE1) engages with its corresponding receptors to activate adenylyl cyclase, bolstering cAMP production and fueling the PKA signaling pathway.
Further downstream, anisomycin acts by inhibiting protein synthesis but also activates stress-activated protein kinases (SAPKs), which may phosphorylate PRR18. Okadaic Acid and Calyculin A, both inhibitors of protein phosphatases, ensure that phosphorylation remains unopposed, thereby maintaining PRR18 in a phosphorylated, active state. Phorbol 12-myristate 13-acetate (PMA) mobilizes protein kinase C (PKC), which is known to phosphorylate a variety of proteins and could contribute to the activation of PRR18. Dibutyryl-cAMP (db-cAMP), as a stable cAMP analog, ensures sustained PKA activation, which is instrumental for the continuous phosphorylation of PRR18. Rolipram and Zaprinast, by inhibiting phosphodiesterase 4 and 5 respectively, elevate cAMP levels, supporting the PKA pathway and thereby PRR18 activation. Vinpocetine, through its inhibition of PDE1, increases both cAMP and cGMP levels, possibly enhancing PKA activity, which in turn can lead to the phosphorylation of PRR18.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine that activates beta-adrenergic receptors, leading to the activation of adenylyl cyclase and a subsequent rise in cAMP levels. The increase in cAMP activates PKA, which can phosphorylate and activate proteins such as PRR18. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which are enzymes that break down cAMP. By inhibiting these enzymes, IBMX leads to an accumulation of cAMP within the cell, potentially activating PKA, which may then lead to the phosphorylation and activation of PRR18. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) binds to its receptors, leading to the activation of adenylyl cyclase and increased cAMP production. This cascade can activate PKA, which in turn could phosphorylate and activate PRR18. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs) such as JNK. Activation of JNK can lead to the phosphorylation of various proteins, potentially including PRR18, thereby activating it. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to an increase in phosphorylation of cellular proteins by kinases. This can result in the enhanced phosphorylation and activation of proteins like PRR18. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A, like okadaic acid, inhibits protein phosphatases 1 and 2A, resulting in hyperphosphorylation of cellular proteins. This can cause the activation of proteins such as PRR18 via increased phosphorylation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a wide range of target proteins. PKC-mediated phosphorylation can lead to the activation of proteins, including PRR18. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cAMP analog that is resistant to degradation by phosphodiesterases. Its presence leads to the prolonged activation of PKA, which can result in the phosphorylation and activation of PRR18. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels in the cell. Elevated cAMP activates PKA, which may phosphorylate and activate PRR18. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases, particularly PDE5, resulting in increased cAMP levels within the cell. This elevation of cAMP can activate PKA, which could lead to the phosphorylation and activation of PRR18. | ||||||